Toll Free: 1-888-928-9744

Biotie Therapies Corp. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Biotie Therapies Corp. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Biotie Therapies Corp. - Product Pipeline Review - 2014', provides an overview of the Biotie Therapies Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biotie Therapies Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biotie Therapies Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biotie Therapies Corp.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Biotie Therapies Corp.'s pipeline products

Reasons to buy

- Evaluate Biotie Therapies Corp.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biotie Therapies Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biotie Therapies Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biotie Therapies Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biotie Therapies Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biotie Therapies Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Biotie Therapies Corp. Snapshot 5
Biotie Therapies Corp. Overview 5
Key Information 5
Key Facts 5
Biotie Therapies Corp. - Research and Development Overview 6
Key Therapeutic Areas 6
Biotie Therapies Corp. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Biotie Therapies Corp. - Pipeline Products Glance 11
Biotie Therapies Corp. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Biotie Therapies Corp. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Biotie Therapies Corp. - Drug Profiles 14
nepicastat hydrochloride 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
tozadenant 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
BTT-1023 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
SYN-114 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
SYN-120 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecules To Inhibit PDE-10 For Schizophrenia 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Biotie Therapies Corp. - Pipeline Analysis 22
Biotie Therapies Corp. - Pipeline Products by Target 22
Biotie Therapies Corp. - Pipeline Products by Route of Administration 24
Biotie Therapies Corp. - Pipeline Products by Molecule Type 25
Biotie Therapies Corp. - Pipeline Products by Mechanism of Action 26
Biotie Therapies Corp. - Recent Pipeline Updates 27
Biotie Therapies Corp. - Dormant Projects 33
Biotie Therapies Corp. - Discontinued Pipeline Products 34
Discontinued Pipeline Product Profiles 34
buprenorphine hydrochloride 34
AWD-12281 34
BTT-1507 34
nitisinone 34
rufinamide 35
Biotie Therapies Corp. - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39
List of Tables
Biotie Therapies Corp., Key Information 5
Biotie Therapies Corp., Key Facts 5
Biotie Therapies Corp. - Pipeline by Indication, 2014 8
Biotie Therapies Corp. - Pipeline by Stage of Development, 2014 9
Biotie Therapies Corp. - Monotherapy Products in Pipeline, 2014 10
Biotie Therapies Corp. - Phase II, 2014 11
Biotie Therapies Corp. - Phase I, 2014 12
Biotie Therapies Corp. - Preclinical, 2014 13
Biotie Therapies Corp. - Pipeline by Target, 2014 23
Biotie Therapies Corp. - Pipeline by Route of Administration, 2014 24
Biotie Therapies Corp. - Pipeline by Molecule Type, 2014 25
Biotie Therapies Corp. - Pipeline Products by Mechanism of Action, 2014 26
Biotie Therapies Corp. - Recent Pipeline Updates, 2014 27
Biotie Therapies Corp. - Dormant Developmental Projects,2014 33
Biotie Therapies Corp. - Discontinued Pipeline Products, 2014 34
Biotie Therapies Corp., Other Locations 36
Biotie Therapies Corp., Subsidiaries 37 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify